Exodus Point Capital Management, LP Lexicon Pharmaceuticals, Inc. Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.3 - $3.58 $414,775 - $1.14 Million	319,058 New	319,058 $766,000
Q1 2023 May 11, 2023	BUY	$1.99 - $2.68 $30,916 - $41,636	15,536 New	15,536 $38,000
Q2 2022 Aug 19, 2022	SELL	$1.31 - $2.69 $21,354 - $43,849	-16,301 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.95 - $3.89 $34,320 - $68,464	-17,600 Reduced 51.92%	16,301 $34,000
Q4 2021 Feb 11, 2022	BUY	$3.81 - $6.16 $36,957 - $59,752	9,700 Added 40.08%	33,901 $134,000
Q3 2021 Nov 15, 2021	SELL	$3.38 - $5.35 $25,813 - $40,857	-7,637 Reduced 23.99%	24,201 $116,000
Q2 2021 Aug 16, 2021	SELL	$4.12 - $5.87 $221,561 - $315,670	-53,777 Reduced 62.81%	31,838 $146,000
Q1 2021 May 17, 2021	BUY	$3.45 - $9.09 $295,371 - $778,240	85,615 New	85,615 $503,000
Q3 2020 Nov 16, 2020	SELL	$1.44 - $2.1 $36,895 - $53,806	-25,622 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.75 - $2.3 $44,838 - $58,930	25,622 New	25,622 $51,000
Q4 2019 Feb 14, 2020	SELL	$3.16 - $5.15 $432,414 - $704,726	-136,840 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$1.2 - $6.66 $164,208 - $911,354	136,840 New	136,840 $412,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $157M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.